Brief: Adial Pharmaceuticals Announces Positive In Vivo Data For Purnovate’S PNV-5030 As A Potential Treatment For Chronic Pain

Azora Therapeutics

26/09/2022 14:48

Sept 26 (Reuters) - Adial Pharmaceuticals Inc  ADIL.O :
    * ADIAL PHARMACEUTICALS ANNOUNCES POSITIVE IN VIVO DATA FOR
PURNOVATE’S PNV-5030 AS A POTENTIAL TREATMENT FOR CHRONIC PAIN
    * ADIAL PHARMACEUTICALS - PNV-5030 REDUCED PAIN IN AN ANIMAL
MODEL
OF CHRONIC PAIN, AS COMPARED TO BOTH PLACEBO AND ACETAMINOPHEN

Source text for Eikon:  ID:nGNXbwlzct 
Further company coverage:  ADIL.O 
 ((Reuters.Briefs@thomsonreuters.com;;))